Share This Page
BACIGUENT Drug Patent Profile
✉ Email this page to a colleague
When do Baciguent patents expire, and when can generic versions of Baciguent launch?
Baciguent is a drug marketed by Pharmacia And Upjohn and is included in one NDA.
The generic ingredient in BACIGUENT is bacitracin. Additional details are available on the bacitracin profile page.
US Patents and Regulatory Information for BACIGUENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | BACIGUENT | bacitracin | OINTMENT;OPHTHALMIC | 060734-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
BACIGUENT: Investment Scenario and Fundamentals Analysis
What is BACIGUENT and how is it positioned commercially?
BACIGUENT is a branded pharmaceutical product marketed in India containing bacitracin zinc (topical antibiotic). Across the Indian market, bacitracin zinc products are typically sold for localized bacterial skin infections, wound care, and related superficial infections where topical antibiotics are used.
Core commercial positioning (typical for bacitracin zinc topicals):
- Use case: localized infections treated without systemic antibiotics.
- Channel: hospital and retail pharmacy supply chains.
- Value driver: physician familiarity, shelf availability, and pack-level pricing discipline rather than patent-driven exclusivity.
Is BACIGUENT protected by strong patent exclusivity?
This is a highly generic-friendly therapeutic area and formulation category.
Practical exclusivity implications:
- Active ingredient maturity: bacitracin zinc has long-standing market presence, which normally translates into limited patent tail risk for new entries and low likelihood of meaningful API-level exclusivity for branded topical SKUs.
- Likely protection stack: at most, product-specific patents (process/formulation, packaging, or local regulations) rather than composition-of-matter coverage.
Investment inference: the brand is exposed to price competition after any credible entry threshold. Returns hinge on manufacturing execution, distribution reach, and clinical guideline fit rather than on patent duration.
What do BACIGUENT fundamentals look like from a drug-structure and market-demand perspective?
Topical antibiotics in general have fundamentals shaped by four forces: usage volume, substitution risk, supply reliability, and regulatory tolerance.
Demand fundamentals
- Patient need profile: localized bacterial skin infections and minor wound-associated contamination where topical antibiotics are used.
- Prescriber behavior: topical antibiotic choice often follows brand availability and past performance rather than new evidence cycles.
- Switching risk: moderate. Patients and prescribers can switch brands quickly if equivalence is accepted.
Supply and manufacturing fundamentals
- Barrier profile: moderate to low compared with complex small molecules or biologics because bacitracin zinc is a mature active ingredient.
- Operational constraint: consistent potency, stability, and low contamination risk in topical preparations.
Competitive structure
- Market pattern: bacitracin topical space usually contains multiple brands and generics.
- Primary competitive lever: price and distribution rather than differentiation.
How should investors underwrite BACIGUENT’s risk factors?
BACIGUENT’s risk profile is dominated by market mechanics rather than long-dated science risk.
Key downside risks
- Generic price pressure: mature active ingredient increases likelihood of competitive entry and margin compression.
- Indication substitution: topical antibiotic selection can shift to other topical agents (for example, where resistance patterns or clinical preferences move).
- Regulatory and quality risk: topical antibiotics require strict quality controls; batch issues can disrupt supply and damage brand trust.
- Margin volatility: pharmacy channel pricing and distributor margins can change quickly under competitive intensity.
Key upside drivers
- Manufacturing scale and cost position: lower unit cost supports price competitiveness without impairing gross margin.
- Distribution density: sustained hospital pull-through and pharmacy shelf dominance.
- SKU and pack engineering: pack sizes that match prescribing and pharmacy purchasing behavior can stabilize revenue per account.
What is the patent and lifecycle strategy implication for BACIGUENT?
For a mature topical antibiotic, lifecycle strategy usually centers on:
- Brand extension through line extensions, pack variants, and channel-specific SKUs.
- Product stewardship in regulatory documentation and pharmacovigilance to maintain market access.
- Cost leadership and supply assurance.
Investment implication: the investment case is less “inventorship and exclusivity” and more “execution and unit economics.” Without strong, enforceable intellectual property, investors should assume structural price compression over time.
How does BACIGUENT fit into broader pharma portfolio math?
Because bacitracin zinc topicals are generally not patent-protected like novel drugs, they are better valued as:
- cash-flow generators (if manufacturing and distribution are optimized),
- defensive lines (stable demand in routine infection management),
- working-capital intensive or not depending on inventory turn and distributor terms.
Portfolio role framing:
- If your thesis is patent-driven upside, BACIGUENT does not fit the profile well.
- If your thesis is manufacturing and commercial execution with controlled downside, it fits better.
What investment scenarios follow from BACIGUENT’s fundamentals?
Below are scenario frameworks consistent with mature active ingredients and branded topical antibiotics.
Base case (most likely)
- Revenue growth tracks market expansion plus modest share retention.
- Gross margin compresses gradually under competitive pricing.
- Net profit depends on cost discipline, distribution terms, and inventory control.
Investor read: treat BACIGUENT like a volume-plus-margin discipline story.
Bull case
- Company defends shelf and hospital usage through supply reliability, service levels, and price stability.
- Packs and channel strategies improve account stickiness.
- Manufacturing cost curve improves (scale, yield, waste reduction), offsetting price cuts.
Investor read: invest or hold only if the business shows cost per unit trending down faster than price.
Bear case
- Competitive entries accelerate, or distributors demand steeper margin concessions.
- Gross margin erodes faster than volume offsets.
- Quality incidents or supply disruptions reduce repeat purchasing.
Investor read: the key metric is gross margin resilience at stable volume, not top-line growth.
What due-diligence metrics matter most for BACIGUENT?
For a mature branded topical antibiotic, the highest-signal metrics are commercial and operational.
Commercial
- Revenue by channel (hospital vs retail)
- Repeat order rates / account retention
- Trade terms and distributor margin pressures
- Pack-level mix (higher share of value packs supports revenue per account)
Operational
- Manufacturing cost per unit and conversion efficiency
- Batch failure rate and on-time delivery
- Inventory turn and write-off exposure
- QA release timelines (stability and microbiological controls)
Competitive
- Number of active competing SKUs in the therapeutic shelf category
- Average selling price trend and promotion frequency
- Switching events tied to drug formularies or hospital tenders
Key Takeaways
- BACIGUENT is a mature bacitracin zinc topical antibiotic product, placing the investment thesis primarily in commercial execution and unit economics, not long-duration patent exclusivity.
- The market structure is typically generic-friendly, so expect price competition and margin pressure unless the supplier holds a strong manufacturing cost and distribution advantage.
- Underwrite upside through cost curve improvements, channel density, and pack mix; underwrite downside through gross margin resilience and supply consistency.
- The correct investor lens is cash-flow durability and risk-managed defensibility, not patent-driven step-change growth.
FAQs
1) Is BACIGUENT a patent-protected innovation drug?
No. Bacitracin zinc topicals are typically part of a mature drug class with limited composition-of-matter exclusivity, so the brand value depends more on execution than on patent duration.
2) What drives demand for BACIGUENT?
Demand is driven by routine use of topical antibiotics for localized bacterial skin infections and superficial wound-associated issues, reinforced by prescriber familiarity and pharmacy availability.
3) What is the biggest financial risk for BACIGUENT holders?
Margin compression from generic and competing-branded pricing, especially if distributor and channel economics worsen faster than volume offsets.
4) What operational factor most impacts reliability of sales?
Manufacturing QA consistency and reliable batch release. Supply disruptions reduce repeat purchasing and can shift patients and accounts to alternative products.
5) What investment strategy fits BACIGUENT best?
A strategy focused on volume stability plus gross margin control, with strong attention to cost per unit, trade terms, and distribution reach.
References
[1] World Health Organization. (n.d.). Antimicrobial resistance: Global report on surveillance. WHO. https://www.who.int/teams/global-antimicrobial-resistance-surveillance-system
[2] FDA. (n.d.). Over-the-counter (OTC) drug products: Topical antibiotics. U.S. Food and Drug Administration. https://www.fda.gov/
More… ↓
